Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study by Savulescu, Camelia et al.
 
 
 
 
 
 
 
Savulescu, C. et al. (2017) Effect of high-valency pneumococcal conjugate 
vaccines on invasive pneumococcal disease in children in SpIDnet 
countries: an observational multicentre study. Lancet Respiratory Medicine, 
5(8), pp. 648-656. (doi:10.1016/S2213-2600(17)30110-8) 
 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it.  
 
 
http://eprints.gla.ac.uk/145249/ 
 
 
 
 
 
 
   Deposited on: 24 July 2019 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of       
           Glasgow 
http://eprints.gla.ac.uk  
 
Title: Impact of higher valency pneumococcal conjugate vaccines on invasive pneumococcal disease in 
children: results of SpIDnet – an observational before/after multicentre study  
Authors: C. Savulescu, MD (1), P. Krizova, PhD (2), A. Lepoutre, MD (3), J. Mereckiene, MD (4), D.F. 
Vestrheim, PhD (5), P. Ciruela, PhD (6), M. Ordobas, MD (7), M. Guevara, PhD (8,9), E. McDonald, PhD 
(10), E. Morfeldt (11), J. Kozakova, MD (2), E. Varon, MD (12), S. Cotter, MD (4), B.A. Winje, PhD (5), C. 
Munoz-Almagro, PhD (9,13), L. Garcia, PhD (7 ), J. Castilla, PhD (8,9), Prof. A. Smith, PhD (14), Prof. B. 
Henriques-Normark, MD (11, 15), L. Pastore Celentano, MD (16), G. Hanquet, PhD (1) and SpIDnet 
group* 
Affiliations:  
1. EpiConcept, France, 47 rue de Charenton, 75012 Paris, France  
2. National Institute of Public Health, Srobarova 48, 100 42 Prague, Czech Republic 
3. Santé publique France, F-94415 Saint-Maurice, France 
4. Health Protection Surveillance Centre, 25-27 Middle Gardiner Street, Dublin 1, Ireland 
5. Norwegian Institute of Public Health, PO Box 4404 Nydalen, 0403 Oslo, Norway 
6. Public Health Agency of Catalunya, c/ Roc Boronat, 81-95, 08005 Barcelona, Spain 
7. Sub-directorate of Health Promotion and Prevention, c/San Martin de Porres, 6, 28009 Madrid, 
Spain 
8. Instituto de Salud Pública de Navarra - IdiSNA, c/ Leyre 15, 31003 Pamplona, Spain 
9. CIBER Epidemiología y Salud Pública, Madrid, Spain 
10. Health Protection Scotland, National Services Scotland, Meridian Court, 5 Cadogan Street, 
Glasgow G2 6QE, Scotland, UK 
11. Public Health Agency of Sweden, Nobelsväg 18, SE-171 82 Solna, Sweden 
12. Centre de Référence du Pneumocoque, Hôpital Européen George Pompidou, 20 rue Leblanc, 
75908 Paris, France 
13. Hospital Sant Joan de Déu. Pº Sant Joan de Deu nº 2. 08950 Esplugues, Barcelona, Spain 
14. Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory, 
New Lister Building, Glasgow Royal Infirmary, G31 2ER, Glasgow, UK 
15. Department of Microbiology, Tumor and Cellbiology, Karolinska Institutet and Department of 
Clinical Microbiology, Karolinska University hospital, SE-171 76-7 Stockholm, Sweden 
16. European Centre for Disease Prevention and Control, Tomtebodavägen 11ª 171 83 Stockholm, 
Sweden 
 
Corresponding author:   
Camelia Savulescu, MD, PhD 
EpiConcept  
47 rue de Charenton, 75012 Paris, France 
c.savulescu@epiconcept.fr  
Telephone: +33620410268 
 
  
Abstract  
Background: The Streptococcus pneumoniae Invasive Disease network (SpIDnet) conducts active 
population-based surveillance for invasive pneumococcal disease (IPD) in nine sites from seven 
European countries. Five sites use 13-valent pneumococcal conjugate vaccine (PCV) only and four use 
PCV13 and PCV10. Vaccination uptake is >90% in six sites and 67-78% in three sites. We measured the 
impact of higher valency PCV (PCV13/PCV10) on IPD in children below five years old.  
Methods: We compared the IPD incidence between the first four years after PCV13/PCV10 introduction 
and the average incidence during the period of heptavalent PCV (PCV7) use, overall and by serotype 
categories. We calculated the pooled incidence rate ratios (IRR) and 95% confidence intervals (CI), using 
random effects meta-analysis.  
Findings: After four years of PCV13/PCV10 use, the pooled IRR was 0·45 for all type IPD, 0·16 for PCV7 
serotypes IPD, 0·17 for IPD caused by 1, 5, 7F serotypes, and 0·41 for 3,6A and 19A serotype IPD. Same 
pattern was observed when restricting to PCV13 sites. The pooled IRR for nonPCV13 serotypes IPD was 
1·12, 1·62, 1·64, and 1·62, for each year post PCV13/PCV10 introduction, respectively.  
Interpretation: Our results indicate a decrease in all type IPD incidence caused by the decline of vaccine 
serotypes. This decline was partially countered by the increase in incidence of nonPCV13 serotypes IPD 
suggesting serotype replacement. Long-term surveillance is needed to monitor the net impact of 
PCV13/PCV10 infant vaccination programmes. 
Funding: SpIDnet multicentre study was co-funded by participating countries and the European Centre 
for Disease Prevention and Control.   
Introduction 
In Europe, countries introduced pneumococcal conjugate vaccination (PCV) at different times, using 
various vaccination schedules and targeting different population groups.1 The introduction of 
heptavalent pneumococcal conjugate vaccine (PCV7) in the childhood vaccination programmes resulted 
in a significant decrease in the incidence of invasive pneumococcal disease (IPD) caused by the vaccine 
serotypes and in an increase of nonPCV7 serotypes such as 19A, 1 or 7F, partly due to the serotype 
replacement phenomenon.2-4 In 2009, two higher valency pneumococcal conjugate vaccines (PCV13 and 
PCV10, panel 1) were licensed in Europe, based on immunogenicity data. These vaccines protect against 
additional three serotypes (for PCV10) or six serotypes (for PCV13). Some of these serotypes such as 19A 
and 7F increased substantially after widespread use of PCV7. However, the immunological response to 
some PCV13 and PCV10 serotypes (common or additional to PCV7) was lower than the established 
thresholds of protection and the association between surrogate markers of protection and clinical 
protection was not always consistent in the pre-marketing studies.5,6  
Monitoring the IPD incidence by serotype in the European Union / European Economic Area (EU/EEA) 
through sensitive and homogenous surveillance systems is essential to provide robust and precise 
measurements of the impact of PCV13/PCV10 vaccination strategies and to allow the early detection of 
potential serotype replacement.7 The heterogeneity of IPD surveillance systems and data collected by 
EU/EEA countries hampered the proper evaluation of PCV vaccination policies at European level, at the 
time PCV7 vaccines became available on the market. Thus, in 2012, the European Centre for Disease 
Prevention and Control (ECDC) promoted the set-up of SpIDnet (Streptococcus pneumoniae Invasive 
Disease network) to conduct active population-based IPD surveillance in children from ten surveillance 
sites in eight countries: The Czech Republic, France, Ireland, Norway, Romania, Spain (Catalonia, Madrid, 
Navarra), Sweden, and the United Kingdom (Scotland). In 2013, seven of these sites had a universal PCV 
vaccination programme in place (five sites with PCV13 and two with PCV10 and PCV13). The vaccine 
uptake exceeded 90% in six sites and 77% in one site (Czech Republic). In two Spanish sites (Navarra and 
Catalonia), the PCV13/PCV10 pneumococcal vaccination was only covered for high risk groups and 
recommended by the professional associations in children under five years of age with a vaccine uptake 
ranging between 67% and 78%. In one site (Romania), the PCV vaccination was included in the national 
immunisation programme but not funded. No site used PCV10 only, and PCV10 uptake was <50% in the 
four sites using it (Table 1). 
To measure the impact of PCV13/PCV10 vaccination programmes in SpIDnet countries, we compared 
the IPD incidence in children under five years of age before and after the introduction of PCV13/PCV10 
vaccination in the childhood immunisation programmes, pooling surveillance data from SpIDnet sites.  
Methods 
Nine SpIDnet sites from seven countries (Czech Republic, France, Ireland, Norway, Spain (Catalonia, 
Madrid, Navarra), Sweden, UK (Scotland)) collected IPD data before and after the introduction of 
pneumococcal conjugate vaccination programmes up to 2013 inclusive, using a common protocol. This 
protocol allowed to standardise case definition, laboratory methods, approaches to ensure an active 
surveillance, data sources, estimation of denominators, completeness and quality of data, and analysis 
between sites. Romania did not meet the criteria to be included in the impact study.   
IPD surveillance systems in the nine SpIDnet sites cover a total of 5·8 million children less than five years 
of age (Table 1). IPD cases from the catchment areas of participating hospitals or laboratories are 
regularly reported, and active contact with data providers is organised in each site. IPD cases must meet 
the ECDC case definition, requiring laboratory confirmation through isolation of Streptococcus 
pneumoniae, detection of bacterial nucleic acid by polymerase chained reaction (PCR) or its antigen in a 
normally sterile body site. Cases with positive antigen test in urine did not meet the ECDC case 
definition, therefore were not included in the analysis. The ECDC case definition for IPD remained 
unchanged since 2002. National or regional reference laboratories perform serotyping of referred 
isolates using capsular reaction with specific antisera (Quellung reaction) or PCR. Serotyping by PCR is 
used in Catalonia, Spain,8 and for 6A/C differentiation in seven sites. Retrospective differentiation of 
serotype 6A and 6C was also performed in six sites. 
Participating sites reported IPD cases aggregated by age, serotype category and calendar year to 
SpIDnet coordination (Table 1). We grouped serotypes in five categories and used them throughout the 
rest of the manuscript: all type IPD, PCV7 serotypes, additional three PCV10/13 (1, 5, 7F) serotypes, 
additional three PCV13 (3, 6A, 19A) serotypes and nonPCV13 serotypes. Non-typeable serotypes were 
included in the nonPCV13 category. We assumed that cases with missing serotype information had the 
same serotype distribution as those with available serotype by site, age and calendar year. For two sites 
that improved surveillance sensitivity with time (Czech Republic and France), we adjusted the incidence 
to the sensitivity of surveillance system before and after the introduction of PCV13/PCV10.  
We compared the IPD incidence in each year after PCV13/PCV10 introduction to three reference 
periods: prePCV7 period (years when no conjugate vaccine was used in each site), PCV7 period (years 
when heptavalent vaccine was used in each site) and the year 2009 (the last year of PCV7 use in seven 
sites and the only PCV7 year in two sites). The year of introduction of the conjugate vaccine was 
included in the reference period according to the vaccination coverage level with the respective vaccine 
(above or below 30% respectively). For each site and period, we calculated the yearly incidence and the 
average incidence over each period by dividing the number of cases by end-year population data. We 
calculated the incidence rate ratios (IRR) per site and their 95% confidence intervals (CI). We computed 
the pooled IRR and the 95% CI by serotype category using random effects meta-analysis. 2 The I-squared 
test of heterogeneity was calculated using the inverse-variance fixed-effect model. 
As primary analysis, we calculated pooled IRR including all reported cases. Subsequently, we performed 
four sensitivity analyses restricted to IPD cases diagnosed by culture, to the six sites with a PCV13/PCV10 
uptake over 90%, to the five sites using PCV13 only, and to six sites with more than two years of PCV7 
use. 
The impact study was embedded in the IPD surveillance systems and conducted according to the ethical 
requirements of each participating site. Ethical approval for surveillance activities is not required in any 
site. We used STATA 13 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: 
StataCorp LP) for all analyses.  
Role of the funding source 
This study used IPD surveillance data collected and monitored by each surveillance site according to a 
ECDC approved standard protocol. The pooled analysis was conducted at the coordination level. ECDC 
reviewed and approved the study report and the manuscript. The corresponding author had full access 
to all study data and has the final responsibility of the manuscript. The decision to submit for publication 
was made by consensus between the coordination, surveillance sites and ECDC. The project received 
public funding alone.  
Results  
In the nine SpIDnet participating sites, IPD surveillance data were available for periods ranging from 
seven years (Czech Republic, Ireland, and Madrid region of Spain) to 14 years (Scotland and France). 
Seven sites provided data for the prePCV7 period (two to six years) and all sites provided data for the 
PCV7 period (one to six years). The PCV13/PCV10 period included four years in seven sites, and three 
years in two sites (Table 1). The median proportion of cases with serotype available varied by site and 
period, was 87%, ranging from 48% to 100% (Table 2). 
The all-type yearly IPD incidence among children less than five years old decreased in all sites in the 
PCV13/PCV10 period as compared to the prePCV7 and PCV7 periods (Table 2).  The pooled IRR of all-
type IPD decreased each year after PCV13/PCV10 introduction compared to the PCV7 period and in the 
first three years as compared to prePCV7 period (Table 3). The PCV7 IPD incidence, that had declined 
after PCV7 introduction, further decreased after PCV13/PCV10 introduction with a median incidence per 
100,000 population of 16·5 (range by site: 7·3-27·3), 3.6 (range: 0-9·7) and 0·5 (range: 0-0·9) in the 
prePCV7, PCV7 and PCV13/PCV10 periods, respectively. After PCV13/PCV10 introduction, the pooled 
PCV7 IRR progressively decreased during the PCV13/10 period (Table 3). The median incidence per 
100,000 of IPD caused by 1, 5, 7F serotypes together increased from 1·2 (range: 1·1-5·5) in the prePCV7 
period to 3·4 (range: 0·3-20·1) in the PCV7 period and declined to 2·1 (range: 0·3-9·8) in the post 
PCV13/PCV10 period. The IRR for these three serotypes decreased annually after PCV13/PCV10 
introduction; the IPD incidence in the fourth year was below the average incidence observed during 
prePCV7 period (Table 3). For the IPD caused by serotypes 3, 6A, 19A together, the median average 
incidence per 100,000 also increased from 2·6 (range: 2·0-23·5) prePCV7 to 3·4 (range: 1·0-17·7) in the 
PCV7 period and declined to 2·4 (range: 1·0-9·3) in the post PCV13/PCV10 period. The related IRR also 
decreased each year, reaching 0·52 and 0·41 in the fourth PCV13/PCV10 year as compared to prePCV7 
and PCV7 periods respectively (Table3). For nonPCV13 serotypes, the median incidence per 100,000 
population continuously increased in each period, from 1·8 (range: 0·5-5·1) in the prePCV7 period to 3·5 
(range: 1·0-14·5) in the PCV7 period and 6·5 (range: 1·7-11·5) in the post-PCV13/PCV10 period. The 
pooled IRR for nonPCV13 serotypes increased each year relative to both reference periods, amounting 
to 2·15, and 1·62 to in the fourth PCV13/PCV10 year as compared to prePCV7 and PCV7 periods 
respectively. The statistical heterogeneity test exceeded 50% in most analyses (Table 3). 
When comparing the incidence in each year post PCV13/PCV10 introduction to the year 2009 as PCV7 
reference period, the pooled IRRs were very close to those compared to the average PCV7 period for all 
type IPD, additional vaccine serotypes and nonPCV13 serotypes IPD. The higher pooled IRR for PCV7 
serotypes when compared to 2009 indicate the additional decrease in this serotypes following PCV7 use 
(Table 3). 
The same pattern in IRR reduction and heterogeneity was observed when restricting the analysis to 
culture positive IPD cases and to sites with high vaccination uptake (Figure 1, Panel A and B). When 
restricting the analysis to sites using PCV13 only or sites that used PCV7 for more than two years (Figure 
2, Panel C and D) the IRR of serotypes 6A, 3 and 19A IPD was 0·24 (95%CI: 0·13; 0·42) and 0·30 (95%CI: 
0·21; 0·42) for the fourth year respectively, compared to 0.41 (95%CI: 0.25; 0.69) for all sites.  
Discussion  
Our results suggest an overall decrease in all type IPD incidence after introduction of PCV13/PCV10 
vaccination, due to a decrease in the incidence of PCV7 and additional serotypes included in higher 
valency PCV vaccines. NonPCV13 serotypes incidence tended to increase over time compared to both 
reference periods and represented more than half of all cases in the PCV13/PCV10 period. Pooling data 
from several European countries enabled the identification of patterns and trends across a wider 
geographical area and resulted in analyses that are more robust than those performed with data from a 
single country. 
The gradual decrease in overall IPD incidence over the first four PCV13/PCV10 years indicates a positive 
overall effect of the vaccination programmes.9 The pooled IRR estimates suggest that replacing PCV7 by 
PCV13/PCV10 reduced the incidence of all type IPD (-43%) and PCV7 serotypes (-84%) in the fourth year 
as compared to the average PCV7 period. These values are in line with the percent decline described in 
the same age group after a similar period of PCV13 use in other countries such as the United States, the 
United Kingdom and Denmark.10-12 The additional impact of PCV13/PCV10 on PCV7 serotypes 
corroborates the high PCV13 effectiveness against PCV7 serotypes reported in several studies.5,13,14 The 
incidence rates of IPD caused by the six additional serotypes of PCV13 vaccines increased in most sites 
after PCV7 introduction and their trends reversed after PCV13/PCV10 introduction, with a 70% decline 
in the fourth PCV13/PCV10 year compared to the PCV7 period. The amplitude of this decline is slightly 
lower than the 80-90% observed in the United States, United Kingdom and Denmark after three or four 
years of PCV13 use.10-12,15 This difference may be explained by the high vaccination coverage reached in 
a short time in these three countries. Indeed, when we restrict the analysis to sites with high vaccination 
coverage, the decline of the six additional serotypes reached 82% in the fourth PCV13/PCV10 year.  
The consistent increase of nonPCV13 serotype incidence in the PCV13/PCV10 period (IRR above one 
which become statistically significant in year 2 to 4) suggests a role of serotype replacement. Our 
findings suggest that nonPCV13 rise is plateauing in the years 3 and 4, although it is difficult to conclude 
that due to overlapping IRR confidence intervals. As we cannot exclude the role of year to year 
fluctuations, we need additional years of surveillance to better characterize the trends in the nonPCV13 
incidence. Other European studies also reported increases in nonPCV13 serotype incidence in children 
after two to four years of PCV13 use.10,12,16,17 It has been argued that PCV13/PCV10 have a lower 
potential to induce serotype replacement of invasive disease than PCV7 because the prevalence of 
nonPCV13 serotypes in nasopharyngeal carriage reached an equilibrium while the invasiveness of these 
serotypes might be lower.18-20 Nevertheless, after the introduction of PCV7 vaccination, serotype 
replacement, although suspected shortly after the vaccine introduction, was only confirmed few years 
later. Currently, no consistent emergence of a specific nonPCV13 serotype has been reported across 
SpIDnet sites or in other reports.10,11,15-17,19 This is also supported by a higher serotype diversity in all 
SpIDnet sites (Simpson diversity index ranging between 80% and 95%, with an overall index of 94%) as in 
another report.17 Long term monitoring of serotype-specific incidence and carriage prevalence is crucial 
to better explore the extent and nature of potential serotype replacement after further use of higher 
valency PCV. 
Several limitations of our study should be mentioned. First, we observed a high degree of heterogeneity 
in IPD incidence across sites. The heterogeneity may be explained by the differences in health care 
systems (clinical practice), vaccination programmes (PCV7 history, current PCV uptake, use of both 
PCV10 and PCV13 vaccines (four sites), and proportion of vaccine serotypes covered by the vaccines), 
case detection and reporting across sites. We believe that the use of a common protocol addressed the 
differences related to data collection and reporting. The persistence of a high heterogeneity in the 
sensitivity analyses including only sites with high vaccination coverage, same vaccine (PCV13) or culture 
positive IPD suggests this is related neither to the vaccine used, nor vaccination uptake, nor to the 
method of IPD diagnosis. However, despite the high heterogeneity, most site-specific IRR showed the 
same pattern across sites. This residual heterogeneity might be related to the differences in health care 
practices such as clinical care protocols, health care access and use of antimicrobials. Even though these 
may differ between sites, they were assumed constant over time and therefore could not influence the 
relative measure of the impact. Second, some sites had more than 20% cases with missing serotype 
information, in spite of increasing serotyping in most sites. We addressed this limitation by assuming the 
same serotype distribution for the cases with missing serotype information by year, serotype category 
and site. However, this approach might have other limitations when the number of cases is low (such as 
not allowing variations when there are zero cases by serotype category). Third, not all sites contributed 
to year 4 due to different PCV13/PCV10 introduction year, which made difficult the comparison across 
post-vaccination years. Fourth, this ecological design may partly attribute to vaccination the effects of 
other factors such as change in the use of antimicrobials or increased awareness of medical 
professionals. We cannot exclude an increased awareness of clinicians to detect IPD in the post-vaccine 
period, which would bias toward underestimating PCV impact.  
In conclusion, the SpIDnet multicentre surveillance, collecting data using a standardised and common 
protocol allowed for the measurement of the impact of PCV13/PCV10 on IPD incidence in children from 
nine sites of seven European countries. This permitted the quantification of decreases in the vaccine 
serotype incidence, and identification of an increase in nonPCV13 incidence despite varying serotype 
dynamics across different countries. Several questions about the effects of higher valency PCV are still 
pending such as their overall effect on healthy individuals versus populations with underlying conditions, 
and the extent of their indirect effect. Therefore, continuous high standard active IPD surveillance in 
children, enhanced surveillance of non-vaccinated age groups, and the inclusion of more sites in SpIDnet 
is essential to elucidate various aspects of PCV effects on IPD epidemiology. This is intended in the 
ECDC-funded extended SpIDnet project aiming to evaluate the long-term use of higher valency PCV, 
until a new generation of vaccines is available.  
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Research in context 
Systematic review on evidence before this study 
We searched Pubmed using the following terms: pneumococcal conjugate vaccine and impact/effect 
with publication date between 1 January 2010 and 8 April 2016 with no language restriction. We 
screened the title and abstract of 637 articles, assessed 45 full articles and finally included 12 
observational studies presenting the impact of higher valency conjugate vaccines on invasive 
pneumococcal disease incidence in children < 5 years in similar settings as SpIDnet. We excluded studies 
that did not calculate impact based on incidence rates, studies based on ICD codes without medical 
validation, conducted in SpIDnet sites or in different settings (outside Europe and North America), or in 
specific populations at higher risk (i.e. native populations). The included studies (Supplementary table 1) 
were divided in two categories: non-SpIDnet European studies (six studies) and other studies (six 
studies).   
Added value of this study 
This is the first multicentre study presenting quantified impact measures for each of the four years after 
higher valency PCV introduction. As compared to PCV7 period, the decline in overall IPD incidence was 
in line with other studies for similar number of years included in the post higher valency PCV period.11, 12, 
21-28 The decrease in all type IPD incidence was however reported to be higher in a PCV10 study 
(Netherlands, -80%) after three PCV10 years and in one out of three US studies (one using a different 
method and both using the late PCV7 period not the whole PCV7 period).25,29 The decrease in vaccine 
serotypes is in line with the other studies, though a slightly higher decrease is described in the US 
(explained by the use of the late PCV7 period as reference).25 The nonPCV13 incidence increase in 
SpIDnet was similar to the increase observed in England & Wales and Israel after the fourth and second 
year of PCV13 introduction, respectively;12, 27 in the other studies the increase in nonPCV13 was non-
significant.  
Compared to prePCV7 period, our results overall and by serotype in the second year after PCV13/PCV10 
introduction were in line with the Israel study,27 while a European PCV10 study reported a higher 
decrease in all type IPD and PCV10 serotypes.30  
Implications of all the available evidence 
SpIDnet multicentre study allows to document the gradual decreases in vaccine types and increases in 
non-vaccine serotypes while more cohorts get vaccinated, and represent an added value compared to 
studies from single countries when the number of cases is low. Our study also presents data compared 
to the pre-PCV7 period to allow for quantifying the impact of combined PCV7 and PCV10/13 vaccination, 
a measure that is rarely made. Harmonizing IPD surveillance or collecting, analysing and presenting data 
in similar ways can provide additional information on the pneumococcal disease epidemiology in the era 
of higher valency PCV vaccines.  
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Panel 1: Serotypes included in the three pneumococcal conjugate vaccines (PCV) used in vaccination programmes up to present  
Vaccine Serotypes 
PCV7  4, 6B, 9V, 14, 18C, 19F, 23F 
PCV10  4, 6B, 9V, 14, 18C, 19F, 23F, 1, 5, 7F 
PCV13  4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, 19A 
PCV13, PCV7 (Prevenar 13, Prevenar, Pfizer); PCV10 (Synflorix, GlaxoSmith-Kline) 
 
  
Table 1: Surveillance characteristics of participating sites, SpIDnet multicentre study 
Site  
 
Characteristic 
Czech Rep France Ireland Norway Scotland Sweden Catalonia Madrid Navarra 
Population <5 
years covered*  
 573,939  2,851,051  365,747  313,215  294,281  579,019 413,181  361,374  34,804 
Type of the 
system 
Laboratory 
and hospital 
based 
Hospital and 
lab-based  
Laboratory
-based 
 
Laboratory 
-based 
 
Laboratory -
based 
 
Hospital and 
laboratory -
based 
Laboratory 
-based 
Hospital and 
laboratory -
based 
Hospital and 
laboratory -
based 
Case definition  ECDC 2012 ECDC 2012 
(except cases 
diagnosed by 
antigen 
detection) 
ECDC 2012 ECDC 2012 
 
ECDC 2012 ECDC 2012 ECDC 2012 ECDC 2012 ECDC 2012 
PrePCV7 years 2007-2008 1998-2003 2007-2008 2007-2008 2000-2005 2006-2008 NA NA 2001-2004 
Site  
 
Characteristic 
Czech Rep France Ireland Norway Scotland Sweden Catalonia Madrid Navarra 
PCV7 
introduction year 
(schedule) 
2005 (3+1) 2003 (3+1) in 
risk groups 
2008 (2+1) 
Sep. 2008 
(2+1)  
2006 (2+1) 2006 (2+1)  2009 (2+1) 
2007 - 2008 in 
some counties  
2001 (3+1) 
for high risk 
groups  
2006 (3+1)  2001 (3+1) for 
high risk groups  
• years of use 2009 2004-2009 2009-2010 2006-2010 2006-2009 2009 2006-2009 2007-2009 2005-2009 
Higher valency 
PCV introduction 
(schedule) 
2010 
PCV13/PCV10 
(3+1) 
2010  
PCV13  
(2+1) 
Dec. 2010 
PCV13 
(2+1) 
2011 
PCV13 
(2+1) 
2010  
PCV13  
(2+1) 
2010 
PCV13/PCV10 
(2+1) 
2010 
PCV13/PCV
10 (3+1) 
2010  
PCV13  
(2+1) 
2010 
PCV13/PCV10† 
(3+1) 
• years of use 2010-2013 2010-2013 2011-2013 2011-2013 2010-2013 2010-2013 2010-2013 2010-2013 2010-2013 
PCV13/PCV10 
uptake (2013)** 
77% 93% 93% 93% 97% 98% 67% 92% 78% 
NA=not available; ECDC=European Centre for Disease Prevention and Control; * 2013 end year population; ** Estimated vaccination coverage at 
24 months, (SC: primary schedule at 12 months); †PCV10 with low coverage.  
Table 2. Number of cases, proportion serotyped and all type IPD incidence by site and period in children < 5 years, included in the impact 
analysis, SpIDnet multicentre study 
Sites Annual average number of cases  
(median and range % serotyped) 
Median (range) annual incidence (per 100,000) 
 prePCV7 period PCV7 period PCV13/PCV10 period prePCV7 period PCV7 period PCV13/PCV10 period 
Czech Republic 65 (82, 82:83) 35 (83, one year) 27 (76, 67:83) 12·6 (11·9:13·4) 6·4 (one year) 4·6 (2·6:7·0) 
France 480 (NA£) 461 (NA£) 346 (NA£) 18·0 (16·8:19·0) 15·4 (14·0:17·0) 12·1 (8·4:16·9) 
Ireland 69 (67, 48:86) 44 (76, 75:77) 41 (63, 59:64)* 21·8 (21·6:21·9) 12·8 (10·1:15·5) 11·5 (10·7:11·8) 
Norway 104 (78, 76:80) 52 (95, 92:100) 24 (96, 95:100)* 35·9 (28·9:42·9) 14·1 (9·9:33·1) 8·3 (6·1:9·1) 
Scotland, UK 75 (96, 84:97) 41 (95, 92:100) 34 (65, 53:89) 28·8 (19·1:35·8) 12·8 (9·4:23·8) 11·8 (9·5:12·2) 
Sweden 81 (88, 81:96) 66 (97, one year) 38 (96, 88:98) 13·9 (13·4:19·9) 12·0 (one year) 6·4 (4·7:9·1) 
Catalonia, Spain NA 231 (75, 68:90) 153 (79, 68:87) NA 58·7 (50·5:64·4) 38·9 (25·2:41·7) 
Madrid, Spain NA 148 (88, 86:89) 79 (87, 82:87) NA 41·8 (35·5:51·5) 19·9 (16·0:30·4) 
Navarra, Spain 17 (98, 89:100) 14 (90, 57:93) 7 (93, 70:100) 64·3 (33·1:78:2) 42·4 (31·7:61·2) 20·0 (14·5:28·7) 
*In Norway and Ireland, the postPCV13/PCV10 period included three years; £ Data available from two different systems; 
NA: not available (prePCV7 data was not available for Madrid and Catalonia, Spain) 
 
Table 3: Pooled IPD Incidence rate ratio (IRR) in children <5 years by postPCV13/PCV10 year compared to prePCV7 and to PCV7 reference 
periods, SpIDnet multicentre study 
Reference 
period  
IPD serotype 
categories 
Sites 
year1 
(N) 
IRR Year 1 
postPCV13/ 
PCV10 
(95%CI) 
I2  
(%) 
Sites 
year2 
(N) 
IRR Year 2 
postPCV13/ 
PCV10 
(95%CI) 
I2  
(%) 
Sites 
year
3 
(N) 
IRR Year 3 
postPCV13/ 
PCV10 
(95%CI) 
I2  
(%) 
Sites 
year4 
(N) 
IRR Year 4 
postPCV13/ 
PCV10 
(95%CI) 
I2  
(%) 
Average 
prePCV7 
period 
All types  7 0·47 (0·33; 0·68) 86·7 7 0·41 (0·28; 0·60) 87·6 7 0·35 (0·24; 0·50) 83·3 5 0·45 (0·39; 0·51) 0·0 
PCV7  7 0·09 (0·04; 0·21) 83·7 7 0·05 (0·03; 0·10) 43·7 7 0·06 (0·04; 0·10) 20·2 5 0·04 (0·03; 0·06) 0·0 
1, 5, 7F 7 1·18 (0·52; 2·67) 75·9 7 0·84 (0·35; 2·00) 71·1 7 0·68 (0·33; 1·38) 55·1 5 0·36 (0·14; 0·98) 50·3 
3, 6A, 19A 7 1·25 (0·86; 1·82) 38·1 7 0·82 (0·53; 1·27) 37·3 7 0·49 (0·34; 0·71) 16·6 5 0·52 (0·38; 0·71) 0·0 
nonPCV13 7 1·59 (0·75; 3·35) 80·0 7 2·36 (1·14; 4·86) 81·5 7 2·20 (1·06; 4·55) 81·5 5 2·15 (1·06; 4·37) 77·3 
Average 
PCV7 
period 
All types  9 0·76 (0·65; 0·90) 57·6 9 0·67 (0·56; 0·81) 64·9 9 0·56 (0·45; 0·68) 66·4 7 0·53 (0·43; 0·65) 59·7 
PCV7  8 0·31 (0·16; 0·59) 80·2 9 0·19 (0·08; 0·45) 83·2 8 0·16 (0·07; 0·34) 77·0 6 0·16 (0·07; 0·40) 79·5 
1, 5, 7F 9 0·68 (0·43; 1·07) 76·4 9 0·56 (0·41; 0·76) 39·9 9 0·36 (0·25; 0·51) 40·5 7 0·17 (0·07; 0·42) 76·6 
3, 6A, 19A 9 1·06 (0·86; 1·30) 17·8 9 0·71 (0·53; 0·96) 39·2 9 0·46 (0·28; 0·77) 71·3 7 0·41 (0·25; 0·69) 66·5 
nonPCV13 9 1·12 (0·75; 1·67) 67·7 9 1·62 (1·10; 2·40) 78·8 9 1·64 (1·18; 2·27) 59·6 7 1·62 (1·09; 2·42) 70·5 
Year 2009 
(last PCV7 
year) 
All types  9 0·77 (0·69; 0·86) 19·2 9 0·68 (0·60; 0·78) 31·6 9 0·56 (0·47; 0·66) 53·0 7 0·52 (0·43; 0·64) 61·7 
PCV7  9 0·57 (0·31; 1·06) 69·0 9 0·39 (0·16; 0·94) 80·0 9 0·31 (0·12; 0·81) 80·5 7 0·40 (0·16; 0·98) 72·0 
1, 5, 7F 9 0·56 (0·40; 0·77) 56·6 9 0·45 (0·34; 0·58) 31·7 9 0·29 (0·23; 0·36) 5·8 7 0·14 (0·05; 0·37) 80·1 
3, 6A, 19A 9 0·97 (0·76; 1·23) 33·5 9 0·64 (0·47; 0·88) 46·0 9 0·45 (0·25; 0·81) 79·2 7 0·41 (0·22; 0·77) 79·0 
nonPCV13 9 0·99 (0·65; 1·52) 73·4 9 1·44 (0·96; 2·17) 76·5 9 1·43 (1·02; 2·01) 65·3 7 1·42 (0·95; 2·13) 73·7 
 
  
Figure 1: Pooled incidence rate ratios for culture positive IPD cases (Panel A), sites with PCV10/PCV13 vaccination uptake >90% (Panel B), sites 
with PCV13 only vaccination programme (Panel C), and sites with more than two years of PCV7 use (Panel D), SpIDnet multicentre study 
(I2 heterogeneity test; IRR=Incidence Rate Ratio)  
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